There was no significant difference in pGSN levels between the control group and 3 study groups according to their clinical scores such as mild, moderate and severe bronchiolitis (p>0.05).
Acute bronchiolitis in children is characterized by a viral upper respiratory prodrome followed by increased respiratory effort and wheezing; while the most common etiologic agent is Respiratory Syncytial Virus (RSV). It is caused by bronchial obstruction because of edema, mucus accumulation and cell damage after virus invasion to the small airways. Depending on inflammation, airway epithelial necrosis occurs, epithelium is replaced with nonciliated epithelium, consequently, secretion to the larger proximal airways is reduced and airway obstruction develops. The diagnosis of bronchiolitis is mostly clinical and usually does not require investigation. Guidelines have classified bronchiolitis into: mild, moderate and severe according to clinical findings.¹ Plasma gelsolin (pGSN) scavenges actin filaments released from cells during inflammation and injury. 2, 3 It was reported that of recombinant human pGSN infusion at appropriate doses can diminish evolving injury or reduce mortality rates in animal models of hyperoxia, burns, and sepsis. [4] [5] [6] Tissue injuries in various organs and diseases lead to prolonged reductions in pGSN levels, which precedes and predicts the development of many of the morbidities experienced by these high risk patients, including acute respiratory distress syndrome, acute lung injury, multiple organ dysfunction syndrome, and sepsis. In such patients, the degree of the reduction in pGSN levels has an inverse relationship with the duration of assisted ventilation, length of intensive care unit stay, overall length of hospital stay, and death. [7] [8] [9] Although bronchiolitis is a clinical entity, there is no known biomarker that predicts the prognosis or survival. The aim of this study was to determine whether pGSN level is associated with viral infections especially in acute bronchiolitis.
Material and Methods

Subjects
This prospective study was conducted between December 1st, 2013 and May 1st, 2014 at Kayseri Training and Research Hospital. The study included 52 patients with acute bronchiolitis and 28 healthy children. Inclusion criteria were as follows: aged between 1 and 24 months, a history of preceding viral upper respiratory infection followed by wheezing and crackles on auscultation, first wheezing episode, and clinical severity score (CSS) ≥ 4. Bronchiolitis was diagnosed on clinical findings. The clinical severity score (CSS) was previously described by Wang et al. 10 in Table I . Exclusion criteria were as follows: chronic cardiopulmonary or neurological disease, premature birth, birth weight <2500 g, history of recurrent wheezing episodes, proven immune deficiency, age of <1 month old or >2 years, proven or suspected acute bacterial infection, previous treatment with bronchodilators or corticosteroids, symptoms >7 days, consolidation or atelectasis on a chest roentgenogram.
The control group comprised 28 healthy children (with similar age/gender) presented to Pediatric General Policlinics for routine health control or vaccination. pGSN level was studied only at baseline in the control group.
The parents of all patients and controls were informed about the study objectives and written informed consent was obtained before inclusion in the study. The ethical aspects were respected and the research was approved by the Ethics and Research Committee of Erciyes University.
Evaluation of pGSN Levels
All plasma samples were frozen at -20° C until assays. Plasma gelsolin levels were measured by a quantitative sandwich enzyme immunoassay method by an ELISA kit (Biomatic, PGSN USA). A micro-plate precoated by an antibody specific for soluble human pGSN was used. Standards and samples were pipetted into the wells and any soluble human pGSN present was bound by the immobilized antibody. After washing away any unbound substances, a biotinylated antibody specific for soluble human pGSN was added to the wells. Following a wash to remove any unbound antibody reagent, a Streptavidin HRP conjugate was added to each well. After washing away any unbound enzyme, a substrate solution was added to each of the wells and color develops in proportion to the amount of soluble pGSN bound in the initial step. The color development was stopped and the intensity of the color was measured at 450 nm. The concentration of pGSN in samples was determined by comparing the O.D. of the samples to the standard curve. Results were expressed as ng/ml.
Statistical analysis
All statistical analyses were performed using the IBM SPSS Statictics 22.0 package program (IBM Corp, Armonk, New York, USA). Data are expressed either as frequencies or median (min-max). Shapiro-Wilk's test was used and a histogram and q-q plot were examined to assess the normality. A two-sided Kruskal Wallis test was applied to compare the differences between groups for continuous variables. A p values less than 0.05 were considered statistically significant. 
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Results
Fifty-two patients were enrolled in the study. There were 20 patients in mild group, 20 patients in moderate and 12 patients in severe group according to CSS.
Five patients had a chest X-ray finding (diffuse interstitial consolidation), while 15 patients received antibiotic therapy, and 20 patients received steroid therapy (all of the severe group and 8 from the moderate group). All the patients had supportive therapy such as hydration, oxygen and salbutamol nebules if indicated.
There were no significant differences between pGSN levels and patient's age (p=0.41), gender (p=0.90, 0.85), hospitalization time (p=0.07), hours of O 2 therapy (p=0.09), doses of ventolin (p=0.09), steroid requirement (p=0.10), antibiotic taken (0.96), CRP levels (p=0.50), white blood counts (p=0.25), chest X-ray findings (p=0.56), having RSV or not (p= 0.43) ( Table II ). All the patients had RSV infections that were detect from nasopharyngeal aspirates.
The control group included 28 healthy children with a mean age of 20 months old. There were no significant differences in pGSN levels between the control group and three patient groups according to clinical scores such as mild, moderate and severe bronchiolitis (p=0.930).
Median pGSN levels at the time of diagnosis was 142.17 ng/ml in the mild group; 143.38 ng/ml in the moderate group, 139.0 ng/ml in the severe group and 140.97 ng/ml in the control group.
Discussion
Bronchiolitis is the most common cause of hospitalization among infants during the first 12 months of life. Approximately 100 000 bronchiolitis admissions occur annually in the United States at an estimated cost of $1.73 billion. 11 RSV alone is estimated to have caused 66000 to 199000 deaths among children younger than 5 years of age. 12 Despite the severity of the disease, it is difficult to define the best possible curative therapy and the only known therapy is often supportive. Research on new biomarkers could help us to determine the severity of bronchiolitis, prognosis, and need for intensive care unit.
Plasma pGSN is an important member of the extracellular actin scavenger system, which binds to actin micro-filaments, released into circulation because of cell death. When actin levels increase in micro circulation, pGSN levels decrease. In bronchiolitis, there is a viral inoculation of respiratory epithelium which leads to inflammation of small airways and sloughing off the epithelium causes varying degrees of bronchial obstruction. In this regard, we planned this study around the question of whether this epithelial damage triggers the scavenger system and hence affects pGSN level.
This is the first study on pGSN levels in patients with acute bronchiolitis. In this study, 16 Although pGSN levels decreased in septic patients, in our study there is no statistically significant difference between three clinic scores of patients with bronchiolitis. Thus, we considered that pGSN levels are changed more often in bacterial infections such as sepsis, than viral infections.
Our study had some limitations. Firstly, the number of patients were limited. Secondly, we could not detect any other viral agents except for RSV because of the insufficiency of our microbiology laboratory. Upcoming information from clinical studies will highlight the specific viral infections and pGSN level correlations with a large number of patients.
In conclusion, pGSN levels did not change in our study. Therefore, we considered that pGSN is a biomarker of bacterial infections and its level does not change in viral infections. In addition, further studies involving viral infections and pGSN would provide a better understanding of the pGSN as a biomarker in bacterial infections and allow the development of new treatment modalities.
